Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1982 Feb;75(2):359–365. doi: 10.1111/j.1476-5381.1982.tb08794.x

Cholinergic action in the nucleus accumbens: modulation of dopamine and acetylcholine release.

J S de Belleroche, I M Gardiner
PMCID: PMC2071605  PMID: 7186823

Abstract

The action of oxotremorine and acetylcholine on the release of dopamine and acetylcholine from tissue slices of the rat nucleus accumbens was studied. Oxotremorine significantly enhanced the release of [14C]-dopamine evoked by 34 mMK+ and the EC50 for this action was 1.5 X 10(-7)M. A maximal enhancement (30%) for this effect was reached at 2 X 10(-7)M oxotremorine. A further enhancement of dopamine release occurred at concentrations of oxotremorine greater than 10(-4)M. The action of oxotremorine on [14C]-dopamine release was calcium-dependent and blocked by atropine (10(-4) M) but not mecamylamine (up to 10(-4) M). Oxotremorine affected [3H]-acetylcholine release differentially, inhibiting the K+-evoked release of [3H]-acetylcholine at concentrations greater than 10(-5) M. The IC50 for this process was 4.3 X 10(-5) M. Acetylcholine (8 X 10(-4) M) showed a similar pattern of action to oxotremorine: it enhanced the K+-evoked release of [14C]-dopamine (50%) and inhibited the K+-evoked release of [3H]-acetylcholine (30%). The mechanism of action of oxotremorine on dopamine release is discussed in terms of a presynaptic receptor-mediated process.

Full text

PDF
359

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andén N. E., Bédard P. Influences of cholinergic mechanisms on the function and turnover of brain dopamine. J Pharm Pharmacol. 1971 Jun;23(6):460–462. doi: 10.1111/j.2042-7158.1971.tb08686.x. [DOI] [PubMed] [Google Scholar]
  2. Bartholini G., Keller H. H., Pletscher A. Drug-induced changes of dopamine turnover in striatum and limbic system of the rat. J Pharm Pharmacol. 1975 Jun;27(6):439–442. doi: 10.1111/j.2042-7158.1975.tb09476.x. [DOI] [PubMed] [Google Scholar]
  3. Cheney D. L., LeFevere H. F., Racagni G. Choline acetyltransferase activity and mass fragmentographic measurement of acetylcholine in specific nuclei and tracts of rat brain. Neuropharmacology. 1975 Nov;14(11):801–809. doi: 10.1016/0028-3908(75)90107-0. [DOI] [PubMed] [Google Scholar]
  4. Christiansen J., Squires R. F. Antagonistic effects of apomorphine and haloperidol on rat striatal synaptosomal tyrosine hydroxylase. J Pharm Pharmacol. 1974 May;26(5):367–369. doi: 10.1111/j.2042-7158.1974.tb09293.x. [DOI] [PubMed] [Google Scholar]
  5. Costall B., Hui S. C., Naylor R. J. Hyperactivity induced by injection of dopamine into the accumbens nucleus: actions and interactions of neuroleptic, cholinomimetic and cholinolytic agents. Neuropharmacology. 1979 Aug-Sep;18(8-9):661–665. doi: 10.1016/0028-3908(79)90032-7. [DOI] [PubMed] [Google Scholar]
  6. Costall B., Naylor R. J. The behavioural effects of dopamine applied intracerebrally to areas of the mesolimbic system. Eur J Pharmacol. 1975 May;32(1):87–92. doi: 10.1016/0014-2999(75)90326-x. [DOI] [PubMed] [Google Scholar]
  7. De Belleroche J., Bradford H. F. Biochemical evidence for the presence of presynaptic receptors on dopaminergic nerve terminals. Brain Res. 1978 Feb 17;142(1):53–68. doi: 10.1016/0006-8993(78)90176-2. [DOI] [PubMed] [Google Scholar]
  8. De Belleroche J., Lugmani Y., Bradford H. F. Evidence for presynaptic cholinergic receptors on dopaminergic terminals: degeneration studies with 6-hydroxydopamine. Neurosci Lett. 1979 Feb;11(2):209–213. doi: 10.1016/0304-3940(79)90130-7. [DOI] [PubMed] [Google Scholar]
  9. Galey D., Simon H., Le Moal M. Behavioral effects of lesions in the A10 dopaminergic area of the rat. Brain Res. 1977 Mar 18;124(1):83–97. doi: 10.1016/0006-8993(77)90865-4. [DOI] [PubMed] [Google Scholar]
  10. Giorguieff M. F., Le Floc'h M. L., Westfall T. C., Glowinski J., Besson M. J. Nicotinic effect of acetylcholine on the release of newly synthesized (3H)dopamine in rat striatal slices and cat caudate nucleus. Brain Res. 1976 Apr 16;106(1):117–131. doi: 10.1016/0006-8993(76)90077-9. [DOI] [PubMed] [Google Scholar]
  11. Jones D. L., Mogenson G. J., Wu M. Injections of dopaminergic, cholinergic, serotoninergic and GABAergic drugs into the nucleus accumbens: effects on locomotor activity in the rat. Neuropharmacology. 1981 Jan;20(1):29–37. doi: 10.1016/0028-3908(81)90038-1. [DOI] [PubMed] [Google Scholar]
  12. Kato G., Carson S., Kemel M. L., Glowinski J., Giorguieff M. F. Changes in striatal specific 3-H-atropine binding after unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurones. Life Sci. 1978 May 8;22(18):1607–1614. doi: 10.1016/0024-3205(78)90056-5. [DOI] [PubMed] [Google Scholar]
  13. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  14. Le Moal M., Galey D., Cardo B. Behavioral effects of local injection of 6-hydroxydopamine in the medial ventral tegmentum in the rat. Possible role of the mesolimbic dopamingergic system. Brain Res. 1975 Apr 25;88(1):190–194. doi: 10.1016/0006-8993(75)90972-5. [DOI] [PubMed] [Google Scholar]
  15. Pijnenburg A. J., van Rossum J. M. Letter: Stimulation of locomotor activity following injection of dopamine into the nucleus accumbens. J Pharm Pharmacol. 1973 Dec;25(12):1003–1005. doi: 10.1111/j.2042-7158.1973.tb09995.x. [DOI] [PubMed] [Google Scholar]
  16. Shute C. C., Lewis P. R. The ascending cholinergic reticular system: neocortical, olfactory and subcortical projections. Brain. 1967 Sep;90(3):497–520. doi: 10.1093/brain/90.3.497. [DOI] [PubMed] [Google Scholar]
  17. Szerb J. C., Somogyi G. T. Depression of acetylcholine release from cerebral cortical slices by cholinesterase inhibition and by oxotremorine. Nat New Biol. 1973 Jan 24;241(108):121–122. doi: 10.1038/newbio241121a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES